Clinical research

sterna biologicals GmbH & Co. KG (sterna) announced that the Company has recently appointed Dr. Marion Wencker as consulting Chief Medical Officer and Dr. Thomas Klaue as consulting Chief Financial Officer.

The three-drug combination of encorafenib, binimetinib and cetuximab significantly improved overall survival in patients with BRAF-mutated metastatic colorectal cancer, according to results of the BEACON CRC Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

Prestige BioPharma announced positive results from a Phase I clinical trial evaluating the pharmacokinetics, safety and immunogenicity of biosimilar candidate HD204 to Avastin.

Imugene Limited, a clinical stage immuno-oncology company, announced new clinical data from the Phase Ib study of its HER-Vaxx cancer vaccine showing cancer fighting antibody and clinical response rates continue to be positive in the patients receiving the optimal biological dose of vaccine.

Prestige BioPharma and Pharmapark LLC announced that the two companies have entered into a binding agreement for the exclusive partnership and supply for the commercialization of Prestige BioPharma´s Trastuzumab biosimilar in the Russian Federation.

Longer than expected PFS for murlentamab when combined with FTD/TPI, particularly in patients with medium/high AMHRII expression, along with immune cascade activation in the tumor micro-environment

Da Volterra, a clinical-stage biopharmaceutical company developing new therapeutics to protect the intestinal microbiota, announced the completion of patient recruitment for its Phase 2 trial ‘SHIELD’ evaluating DAV132 in patients receiving antibiotics.

Median progression-free survival for patients receiving Braftovi Triplet was 4.3 months compared to 1.5 months.

Innovent Biologics, Inc., a world-class biopharmaceutical company that develops and commercializes high quality medicines, presented the research data on the treatment of relapsed or refractory extranodal NK/T cell lymphoma with sintilimab, co-developed with Eli Lilly and Company and key data from six other clinical studies were presented at the 55th Annual Meeting of the American Society of Clinical Oncology by oral presentation and posters.

Auris Medical Holding Ltd. announced that it has completed enrollment in its Phase 1b proof-of-concept trial of AM-201, the Company’s investigational drug for the prevention of antipsychotic-induced weight gain and somnolence.